Shockwave Medical Stock Price, News & Analysis (NASDAQ:SWAV)

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SWAV shares.
View SWAV analyst ratings or view top-rated stocks.

10 brokerages have issued 12-month price targets for Shockwave Medical's stock. Their SWAV share price targets range from $218.00 to $315.00. On average, they anticipate the company's share price to reach $263.00 in the next year. This suggests a possible upside of 52.5% from the stock's current price.
View analysts price targets for SWAV or view top-rated stocks among Wall Street analysts.

Shockwave Medical's stock was trading at $205.61 at the beginning of the year. Since then, SWAV shares have decreased by 16.1% and is now trading at $172.49.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our SWAV earnings forecast.

Shockwave Medical, Inc. (NASDAQ:SWAV) posted its quarterly earnings data on Monday, November, 6th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.11. The firm earned $186.02 million during the quarter, compared to analysts' expectations of $184.71 million. Shockwave Medical had a net margin of 36.33% and a trailing twelve-month return on equity of 42.41%. The business's revenue for the quarter was up 41.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.92 EPS.

ETFs with the largest weight of Shockwave Medical (NASDAQ:SWAV) stock in their portfolio include Neuberger Berman Disrupters ETF (NBDS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), First Trust Indxx Medical Devices ETF (MDEV), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Alger Mid Cap 40 ETF (FRTY), WisdomTree U.S. Growth & Momentum Fund (WGRO) and First Trust Health Care AlphaDEX Fund (FXH).

8 employees have rated Shockwave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

(SWAV) raised $75 million in an initial public offering on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Shockwave Medical's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (6.85%), Wellington Management Group LLP (4.89%), Artisan Partners Limited Partnership (3.80%), Invesco Ltd. (1.92%), Allspring Global Investments Holdings LLC (1.76%) and Morgan Stanley (1.17%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sara Toyloy and Trinh Phung.
View institutional ownership trends.

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.